Printer Friendly

IMMUNOMEDICS REPORTS FIRST CLINICAL RESULTS OF LYMPHOMA IMAGING AGENT

IMMUNOMEDICS REPORTS FIRST CLINICAL RESULTS OF LYMPHOMA IMAGING AGENT
 WARREN, N.J., March 9 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) presented, for the first time, clinical results of the company's lymphoma imaging agent, ImmuRAID(TM)-LL2, at the International Conference on Monoclonal Antibody Immunoconjugates for Cancer in San Diego. At one of the clinical sites of a Phase I/II trial being conducted in the United States and Europe, 88 percent of the lymphomas were detected in the eight patients with limited disease imaged using ImmuRAID-LL2.
 ImmuRAID-LL2 consists of a monoclonal antibody fragment, specific to B-cell lymphomas, labeled with technetium-99m. All of Immunomedics' imaging agents, including ImmuRAID(TM)-CEA for imaging colorectal cancers, currently under review at the U.S. Food and Drug Administration, consists of a monoclonal antibody fragment directly labeled by a simple, rapid proprietary method with the low cost, widely available radioisotope, technetium-99m.
 Dr. Carl Pinsky, vice president, medical affairs, explained, "These results indicate that this imaging agent may be more diagnostic of lymphomas than other available imaging methods. Only a small dose of antibody (I mg.) was needed to detect lymphomas within three hours after injection. A recent HIV-positive patient with lymphoma also showed antibody targeting, thus encouraging us to begin therapy trials of lymphoma in AIDS patients."
 Over 35,000 new cases of lymphoma are diagnosed each year in the United States, and many of these patients may be saved through early and accurate diagnosis and aggressive therapy. With the occurrence of lymphomas in longer-surviving AIDS patients, an increase in lymphomas is being experienced in the United States. The company believes this is the only antibody-based lymphoma imaging kit in clinical trials and has applied to the U.S. Food and Drug Administration for Orphan Drug designation for ImmuRAID-LL2.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections.
 -0- 3/9/92
 /CONTACT: Joseph Schepers of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics Inc. ST: New Jersey IN: MTC SU:


CK-KW -- NY035 -- 6341 03/09/92 11:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1992
Words:374
Previous Article:ROSS STORES ANNOUNCES MAJOR OPENING BLITZ IN WASHINGTON
Next Article:ROSS 'DRESS FOR LESS' OPENS IN LOS ANGELES
Topics:


Related Articles
IMMUNOMEDICS REPORT NEW RESULTS OF LUNG CANCER AND LYMPHOMA IMAGING AGENTS
IMMUNOMEDICS AWARDED ORPHAN DRUG DESIGNATION FOR LYMPHOMA IMAGING AGENT; MAY DETECT LYMPHOMAS IN HIV-INFECTED PATIENTS
IMMUNOMEDICS REPORTS PROMISING LYMPHOMA THERAPY RESULTS; CLINICAL FINDINGS PRESENTED AT ANNUAL NUCLEAR MEDICINE MEETING
IMMUNOMEDICS REPORTS LYMPHOMA IMAGING AND THERAPY TEST RESULTS POSITIVE PHASE II STAGING AND THERAPY FINDINGS
IMMUNOMEDICS REPORTS ON LYMPHOMA IMAGING AND THERAPY PROGRESS AT CANCER CONFERENCE
IMMUNOMEDICS MAKES ADVANCES IN ANTIBODY RECONSTRUCTION AND HUMANIZATION; PROGRESS IN CANCER THERAPY PROGRAMS REPORTED
Immunomedics Reports Progress in Product Commercialization and Cancer Therapeutics at Annual Meeting of Shareholders
Immunomedics Appoints Dr. Morton Coleman to Board of Directors.
Immunomedics' Lymphoma Therapeutic Reported to Induce Significant Responses In Patients with Advanced Non-Hodgkin's Lymphoma.
Immunomedics Receives Up-Front Payment of $18MM From Amgen.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters